drugset / Trial / NCT02021669
Omega-3 for Depression and Other Cardiac Risk Factors - 2
Phase 2
Completed
144 enrolled
Washington University School of Medicine
National Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this 10 week randomized, placebo-controlled, double-blind clinical trial is to determine whether antidepressant augmentation with two grams of EPA omega-3 per day is superior to antidepressant therapy alone for major depression in patients with coronary heart disease (CHD).
Timeline
- Start
- 2014-05-14
- Primary completion
- 2018-09-13
- Completion
- 2018-09-13
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eicosapentaenoic acid | Small molecule | 2 g | — |
| Background | Sertraline | Small molecule | 50 mg | — |